The global Atovaquone market size is predicted to grow from US$ 215 million in 2025 to US$ 312 million in 2031; it is expected to grow at a CAGR of 6.4% from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

Atovaquone is used to prevent or treat a serious lung infection called Pneumocystis pneumonia (PCP). This medication helps to stop infection symptoms such as fever, cough, tiredness, and shortness of breath.

United States market for Atovaquone is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Atovaquone is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Atovaquone is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Atovaquone players cover GSK, Lupin, Apotex, Amneal Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

Infinity Market Research newest research report, the Atovaquone Industry Forecast looks at past sales and reviews total world Atovaquone sales in 2024, providing a comprehensive analysis by region and market sector of projected Atovaquone sales for 2025 through 2031. With Atovaquone sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Atovaquone industry.

This Insight Report provides a comprehensive analysis of the global Atovaquone landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Atovaquone portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Atovaquone market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Atovaquone and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Atovaquone.

This report presents a comprehensive overview, market shares, and growth opportunities of Atovaquone market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

    250mg
    500mg

Segmentation by Application:

    Hospital
    Drug Store

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration.

    GSK
    Lupin
    Apotex
    Amneal Pharmaceuticals

Key Questions Addressed in this Report

What is the 10-year outlook for the global Atovaquone market?
What factors are driving Atovaquone market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Atovaquone market opportunities vary by end market size?
How does Atovaquone break out by Type, by Application?